# Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

> **NCT00662649** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 920 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Fingolimod 0.5 mg
- **DRUG:** Fingolimod 1.25 mg

## Key facts

- **NCT ID:** NCT00662649
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 920 (ACTUAL)
- **Last updated:** 2012-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662649, "Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00662649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*